Emerging Options for High-Risk Non–Muscle Invasive Bladder Cancer

Home » Emerging Options for High-Risk Non–Muscle Invasive Bladder Cancer

Dr. Katie Murray highlights the expanding treatment landscape for high-risk non–muscle invasive bladder cancer, especially for patients who are unresponsive to BCG. Options now include BCG re-challenge, doublet intravesical chemotherapy, systemic immunotherapy with pembrolizumab, intravesical gene-based therapies, and recently FDA-approved intravesical devices. Treatment decisions consider efficacy, side effect profiles, and administration schedules, while radical cystectomy remains the definitive option for patients who do not respond to these therapies. Sequencing and combination of these therapies are key questions shaping future care strategies.

Share the Post:

Related Posts

Dr. Brian Rini featured image

ASCO GU 2026 Preview: HIF Inhibitors Redefine Kidney Cancer

Dr. Brian Rini previews major kidney cancer data at ASCO GU, led by positive phase 3 LIGHTSPARK trials highlighting the

AI, Immunotherapy, and Early Intervention: Charting Oncology’s 2026 Trajectory

As oncology enters 2026, the field is shifting from reactive treatment toward anticipatory, precision-driven care. In this article, experts highlight a convergence of advances in early detection, biologically targeted interventions, engineered immunotherapies, and artificial intelligence, all designed to detect and intercept cancer before it manifests clinically. Multimodal diagnostics (including circulating tumor DNA, radiomics, and AI-enhanced pathology) promise unprecedented accuracy in risk stratification and treatment planning. Concurrently, immunotherapy is evolving from broad cytotoxic approaches to adaptable, biology-matched cellular and vaccine platforms. Equitable implementation remains a priority, with innovations in community-based screening, tele-oncology, and metabolic health integration ensuring that breakthroughs reach diverse populations. Collectively, 2026 is poised to redefine oncology practice: earlier interventions, smarter therapeutics, computational augmentation, and inclusive delivery will guide the next generation of cancer care.